(Reuters) – Moderna Inc said on Thursday that waiving intellectual property rights on COVID-19 vaccines will not help boost supply in 2021 or 2022, a day after U.S. President Joe Biden backed a proposed waiver that is aimed at giving poorer companies access.
(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
